Toward Precision Medicine in MASLD: Evolution of Disease Subtyping
Seminars in Liver Disease · 2026-06 · 46 (02) · 196-213
DOI: 10.1055/a-2926-5401 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 07.08.2026. Verfasst von Ting Feng und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Guangdong Pharmaceutical University, Department of Gastroenterology, Guangdong, People's Republic of China, Guangzho…. Hauptthemen laut MEDLINE: Precision Medicine, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, The National Natural Science Foundation of China.
Abstract (Originalsprache)
Traditional classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) based on histology or biochemical traits are insufficient to capture its complexity, and clinical strategies rely on generalized treatment approaches that may not target to patient heterogeneity. As MASLD is a highly prevalent and heterogeneous condition with diverse clinical trajectories and outcomes ranged from liver-related complications to multiple extrahepatic complications, emerging approaches integrating clinical features, genotypes, multi-omics (microbiota, metabolomics, proteomics, and related post-translational modifications), machine learning–based clustering, and molecular profiling have enabled more refined disease subtyping. This review underscores novel subtyping frameworks of MASLD beyond traditional methods, focusing on their clinical relevance and translational potential. We further identify gaps in standardization across studies, the limitations of existing models, and highlight the need for integrative, longitudinal approaches to improve precision medicine. In conclusion, clustering subtypes might facilitate risk stratification and guide personalized therapeutic strategies to prioritize these expensive treatments to the right phenotype of MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Department of Gastroenterology, Guangdong, People's Republic of China, Guangzhou.
- The Fifth People's Hospital of Shunde District, Department of Gastroenterology, Guangdong, People's Republic of China, Foshan.
- The First Affiliated Hospital of Sun Yat-sen University, Department of Geriatrics, Guangdong, People's Republic of China, Guangzhou.
- The First Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangdong, People's Republic of China, Guangzhou.
ORCID-Profile: Junzhao Ye
Förderung
- China Postdoctoral Science Foundation
- The National Natural Science Foundation of China
Zitieren
APA
Feng, T., Li, J., Ma, X., & Ye, J. (2026). Toward Precision Medicine in MASLD: Evolution of Disease Subtyping. Seminars in Liver Disease, 46(02), 196-213. https://doi.org/10.1055/a-2926-5401
Vancouver
Feng T, Li J, Ma X, Ye J. Toward Precision Medicine in MASLD: Evolution of Disease Subtyping. Seminars in Liver Disease. 2026;46(02):196-213. doi:10.1055/a-2926-5401
BibTeX
@article{Feng2026,
author = {Feng, Ting and Li, Jiaming and Ma, Xiaoyi and Ye, Junzhao},
title = {Toward Precision Medicine in MASLD: Evolution of Disease Subtyping},
journal = {Seminars in Liver Disease},
year = {2026},
volume = {46},
number = {02},
pages = {196--213},
doi = {10.1055/a-2926-5401}
}
EUVIMED